Danaher to acquire Cepheid for $4B

Tuesday, September 13, 2016

Danaher has entered into a definitive merger agreement with Cepheid pursuant to which Danaher will acquire all of the outstanding shares of Cepheid for $53.00 per share in cash, or a total enterprise value of approximately $4 billion including indebtedness and net of acquired cash.  

[Read More]

Companion diagnostics are here to stay

Monday, December 7, 2015

The Pulse on Global Trials by Matthew Howes

The story of personalized medicine has evolved from folklore to popular science, and is destined to become classic medical literature.

[Read More]

Cepheid, FIND, Rutgers collaborate on Xpert MTB/RIF test

Wednesday, October 29, 2014

Cepheid, a Sunnyvale, Calif.-based molecular diagnostics company, FIND, a Switzerland-based international nonprofit organization and Rutgers New Jersey Medical School are collaborating to develop Xpert MTB/RIF Ultra, a next-generation test for Mycobacterium tuberculosis (TB) with increased sensitivity to aid in detection of patients with smear-negative TB, which often is associated with HIV co-infection. The collaboration also is receiving additional support from the National Institute of Allergy and Infectious Diseases at the NIH.

[Read More]